|
|
Article: AMGEN PREVAILS OVER TKT, AVENTIS IN EPO PATENT INFRINGEMENT CASE.(Amgen Inc., Transkaryotic Therapies Inc., Aventis Pharma AG)
- Article from:
- BIOWORLD Today
- Article date:
- January 23, 2001
- Author:
CopyrightCOPYRIGHT 2001 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
U.S. District Court of Massachusetts Judge William Young ruled in favor of Amgen Inc. in its three-year patent dispute with Transkaryotic Therapies Inc. and Aventis Pharma AG late Friday, siding with Amgen on eight claims of patent infringement related to three patents.
The patents at issue cover Epogen alfa, Amgen's billion-dollar blockbuster anemia therapeutic, a recombinant form of erythropoietin, a red blood cell production-regulating hormone.
TKT officials, however, said the war is far from over, and vowed to turn the ruling they called "interim" around on appeal.
Analysts call the decision a decisive round for Amgen, and some say the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Bayer Schering Pharma AG Will Terminate ...
PR Newswire;
June 4, 2007 ;
700+ words
... ... PRNewswire-FirstCall/ -- Bayer Schering Pharma AG, Berlin, Germany will terminate its ... Stockholders' Meeting of Bayer Schering Pharma AG on January 17, 2007 resolved to effect ... to the SEC means that Bayer Schering Pharma AG will no longer be subject to the specialized ...
|
|